• For Patients
  • Sign Up for Updates
  • Shopping cart

MONISTAT® for Healthcare Professionals

  • Explaining VVC
  • Efficacy Data
  • Peer-Led Webinars
  • Products
  • Samples & Coupons

MONISTAT® provides the broadest treatment of yeast infections**, more than Diflucan® and Terazol® View the data

View the data

MONISTAT® relieves your patients' yeast infection symptoms 4x faster while curing just as effectively as the leading prescription1*†

View the study

MONISTAT® may be appropriate for more types of patients2* §

See why

MONISTAT® treats more species of yeast with less drug resistance2,3‡

View the data

Learn why MONISTAT® is just as effective as fluconazole

Order free samples, coupons and patient education

See MONISTAT® treatment options

Sign up to receive email updates

Monistat® - No Big Deal Commercial

View the latest MONISTAT® commercial

  • Sitemap
  • Privacy Policy
  • Contact Us

This website is intended for healthcare professionals in the US or its territories.

© 2015 Insight Pharmaceuticals, LLC, Tarrytown, NY, a Prestige Brands company.

*Compared to prescription fluconazole
**of all non-compounded drug products Diflucan® is a registered trademark of Pfizer Inc. and Terazol® is a registered trademark of Johnson & Johnson
†Based on a clinical study with MONISTAT® 1 Combination Pack Ovule® treatment vs the leading prescription product.
‡Per 2015 CDC Guidelines, options for first-line therapy of non-albicans vulvovaginal candidiasis (VVC) include longer duration therapy (7-14 days) with a non-fluconazole azole regimen.
§2015 CDC Guidelines recommend the use of 7-day topical azole therapies for treatment of vulvovaginal candidiasis (VVC) in pregnant women.

REFERENCES: 1. van Heusden AM, Merkus HM, Corbeij HS, et al. Single-dose oral fluconazole versus single-dose topical miconazole for the treatment of acute vulvovaginal candidosis. Acta Obstet Gynecol Scand. 1990;69(5):417-422. 2. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. http://www.cdc.gov/std/tg2015/tg-2015-print.pdf. Published June 5, 2015. Accessed August 14, 2015. 3. Marchaim D, Lemanek L, Bheemreddy B, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407-1414. 4. Mintz, Martens MG. Prevalence of non-Albicans Candida infections in women with recurrent vulvovaginal symptomatology. Advances in Infectious Diseases. 2013;3(4):238-242. 5. Data on file. Insight Pharmaceuticals LLC, a Prestige Brands company. Tarrytown, NY; 2015. 6. Samra-Latif OM. Vulvovaginitis. http://emedicine.medscape.com/article/2188931-overview. Published March 27, 2014. Accessed March 12, 2015.